✦ LIBER ✦

Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma

✍ Scribed by Kapoor, P; Kumar, S; Mandrekar, S J; Laumann, K M; Dispenzieri, A; Lacy, M Q; Dingli, D; Gertz, M A; Kyle, R A; Greipp, P R

Book ID: 109887477
Publisher: Nature Publishing Group
Year: 2011
Tongue: English
Weight: 167 KB
Volume: 25
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2011.54

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rates of venous thromboembolism in multi

Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis

✍ M. CARRIER; G. LE GAL; J. TAY; C. WU; A. Y. LEE 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

Future drug developments in multiple mye

Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies

✍ Gareth Morgan 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 214 KB

The introduction of thalidomide, lenalidomide, and bortezomib has changed the way that multiple myeloma (MM) is treated and has greatly improved survival outcomes. These novel agents are often used in combination with conventional drugs, such as dexamethasone, to optimize clinical responses; however

Similar efficacy of thalidomide- and bor

✍ Marta Krejci; Evzen Gregora; Jan Straub; Jiri Minarik; Vlastimil Scudla; Zdenek 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 167 KB

Effect of thalidomide therapy on bone ma

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma

✍ Kumar, S; Witzig, T E; Dispenzieri, A; Lacy, M Q; Wellik, L E; Fonseca, R; Lust, 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 151 KB

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

The clinical impact and molecular biolog

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy

✍ Kevin D. Boyd; Fiona M. Ross; William J. Tapper; Laura Chiecchio; GianPaolo Dagr 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 1 views

## Abstract Hemizygous deletion of 17p (del(17p)) has been identified as a variable associated with poor prognosis in myeloma, although its impact in the context of thalidomide therapy is not well described. The clinical outcome of 85 myeloma patients with del(17p) treated in a clinical trial incor